When asked how Opko discovered the new formulation, Frost indicated it was one of many successful acquisitions his company has made over the years. He also cited Claros, an acquisition completed in October 2011, as another such highly lucrative deal. Okpo has also partnered with several larger drug makers and will share in the revenue on drugs developed through their combined efforts. When asked what's next for his company, Frost said Opko is nearing completion of its 4K test for prostate health. He said investors should be looking for more on that front in the "near future." Cramer continued his support for Opko, saying the company and Frost have a proven track record of creating value for their shareholders as well as an uncanny ability to spot and acquire small companies with breakthrough products before the big boys take notice.